



MMWRTM

Morbidity and Mortality Weekly Report

Surveillance Summaries

November 14, 2003 / Vol. 52 / No. SS-11

Surveillance for Selected Maternal Behaviors and Experiences Before, During, and After Pregnancy

Pregnancy Risk Assessment Monitoring System (PRAMS), 2000



The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

General: Centers for Disease Control and Prevention. *Surveillance Summaries*, November 14, 2003. MMWR 2003;52(No. SS-11).

Specific: [Author(s)]. [Title of particular article]. In: *Surveillance Summaries*, November 14, 2003. MMWR 2003;52(No. SS-11):[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, M.D., M.P.H.
Director

Dixie E. Snider, Jr., M.D., M.P.H.
(Acting) Deputy Director for Public Health Science

Susan Chu, Ph.D., M.S.P.H.
(Acting) Associate Director for Science

Epidemiology Program Office

Stephen B. Thacker, M.D., M.Sc.
Director

Division of Public Health Surveillance and Informatics

Daniel M. Sosin, M.D., M.P.H.
Director
Associate Editor, Surveillance Summaries

Office of Scientific and Health Communications

John W. Ward, M.D.
Director

Editor, MMWR Series

Suzanne M. Hewitt, M.P.A.
Managing Editor, MMWR Series

C. Kay Smith-Akin, M.Ed.
Lead Technical Writer/Editor

Lynne McIntyre, M.A.L.S.
Project Editor

Beverly J. Holland
Lead Visual Information Specialist

Malbea A. LaPete
Visual Information Specialists

Kim L. Bright, M.B.A.
Quang M. Doan, M.B.A.

Erica R. Shaver
Information Technology Specialists

CONTENTS

Introduction	2
Methods	2
Results	4
Discussion	6
Conclusion	11
References	13
Appendix	15

Surveillance for Selected Maternal Behaviors and Experiences Before, During, and After Pregnancy

Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

Letitia M. Williams, M.P.H.¹

Brian Morrow, M.S.²

Amy Lansky, Ph.D.²

Laurie F. Beck, M.P.H.¹

Wanda Barfield, M.D.²

Kristen Helms, M.S.P.H.¹

Leslie Lipscomb, M.P.H.²

Nedra Whitehead, Ph.D.²

¹Computer Sciences Corporation (Contracting company with CDC)

²Division of Reproductive Health

National Center for Chronic Disease Prevention and Health Promotion

Abstract

Problem/Condition: Various maternal behaviors and experiences are associated with adverse health outcomes for both the mother and the infant. These behaviors and experiences can occur before pregnancy (e.g., insufficient intake of folic acid), during pregnancy (e.g., complications requiring hospitalization, such as high blood pressure), and after pregnancy (e.g., inadequate follow-up of infants who were discharged early). Information regarding maternal behaviors and experiences is needed to monitor trends, to enhance the understanding of the relations between behaviors and health outcomes, to plan and evaluate programs, to direct policy decisions, and to monitor progress toward *Healthy People 2010* objectives (US Department of Health and Human Services. *Healthy People 2010*. 2nd. ed. With understanding and improving health and objectives for improving health [2 vols.]. Washington DC: US Department of Health and Human Services, 2000).

Reporting Period Covered: This report covers data for 2000.

Description of System: The Pregnancy Risk Assessment Monitoring System (PRAMS) is an ongoing, state- and population-based surveillance system designed to monitor selected self-reported maternal behaviors and experiences that occur before, during, and after pregnancy among women who deliver a live-born infant in 31 states and New York City. PRAMS employs a mixed-mode data collection methodology; as many as three self-administered surveys are mailed to a sample of mothers, and nonresponders are followed up with a telephone interview. Self-reported survey data are linked to selected birth certificate data and weighted for sample design, nonresponse, and noncoverage to create annual PRAMS analysis data sets. PRAMS data can be used to produce statewide estimates of various perinatal health behaviors and experiences among women delivering a live infant. Four indicators for the year 2000 (multivitamin use, pregnancy-related complications, infant checkup, and postpartum contraceptive use) from 19 states are examined in this report.

Results: In 2000, the prevalence of multivitamin use ≥ 4 times per week in the month before pregnancy ranged from 25.0% to 40.7% across the 19 states. Prevalence of pregnancy-related complications requiring hospitalization ranged from 8.8% to 16.3%. Prevalence of infant checkups within 1 week of early (≤ 48 hours) hospital discharge ranged from 51.5% to 88.6%. Prevalence of postpartum contraceptive use ranged from 77.9% to 89.9%.

Interpretation: PRAMS data indicate that 19 states are well below the *Healthy People 2010* objective for folic acid consumption, as measured by multivitamin use. Data for infant checkups indicate that guidelines for care are not being followed for as many as half of those discharged early. However, data for additional years are needed to assess trends in these four indicators.

Public Health Action: State maternal and child health programs can use these population-based data to monitor progress toward *Healthy People 2010* objectives, evaluate adherence to guidelines for care, and assess changes in prevalence of other health behaviors. The data can be shared with policy makers to direct policy decisions that might affect the health of mothers and infants. By providing data on maternal behaviors and experiences that are associated with adverse outcomes, PRAMS supports the activities of two CDC initiatives—to promote safe motherhood and to reduce infant mortality and low birthweight.

Introduction

Various behaviors and experiences are associated with adverse health outcomes for both the mother and infant. These experiences can occur before, during, and after pregnancy. For example, insufficient folic acid consumption before conception and in early pregnancy can increase the incidence of neural tube defects (1). Severe complications during pregnancy contribute to maternal and infant morbidity and mortality (2). Because serious medical conditions, such as sepsis, congenital heart disease, and jaundice, become apparent 24–72 hours after birth, infants who are discharged early (≤ 48 hours) from the hospital should receive a medical visit within 1 week of discharge (3–5). Postpartum contraceptive use is a key factor in spacing births for maximum health benefits.

The Pregnancy Risk Assessment Monitoring System (PRAMS) was initiated in 1987 and is administered by CDC's National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, in collaboration with state health departments. PRAMS is an ongoing, state- and population-based surveillance system designed to monitor selected self-reported maternal behaviors and experiences that occur before, during, and after pregnancy among women who deliver a live-born infant.

The PRAMS questionnaire is revised periodically to reflect changing priorities and emerging issues. Each revision is referred to as a phase. The data highlighted in this report were collected with the Phase Four version of the questionnaire, which was implemented with the 2000 birth cohort. The four topics presented in this report represent three new indicators and one revised indicator from the PRAMS survey. The new indicators are multivitamin use, infant checkups within 1 week of hospital discharge among those discharged within 48 hours, and postpartum contraceptive use. The revised indicator is pregnancy-related complications requiring hospitalization. Prevalence estimates are presented by state and by selected demographic characteristics (age, race, Hispanic ethnicity, education, and Medicaid status). Annual reports that highlight key PRAMS findings from previous years are also available (6–11).

The data presented in this report can be used to assist in program planning and evaluation, to inform policy decisions, and to monitor progress toward *Healthy People 2010* objectives (12). By providing data concerning maternal behaviors and experiences that are associated with adverse outcomes, PRAMS supports the activities of two CDC initiatives — to promote safe motherhood and to reduce infant mortality and low birthweight.

Methods

Project Description

PRAMS was originally implemented in 1987 to help state health departments establish and maintain an epidemiologic surveillance system of selected maternal behaviors and experiences to supplement data from vital records. In the health departments, PRAMS program structures cross several existing organizational units, including maternal and child health and vital statistics. Since its inception, the program has expanded from six to 32 participating health departments in 2003. This number includes 29 states and one city (New York City) that conduct the traditional PRAMS surveillance and two states that recently completed a point-in-time survey. One state conducts the traditional PRAMS surveillance as well as additional PRAMS activities. Live births in these states and city represent approximately 62% of all live births in the United States.

Data Collection

All participating states use a standardized data collection method developed by CDC. Every month, a stratified sample of 100–300 new mothers is selected from eligible birth certificates in each state. PRAMS employs a mixed-mode data collection methodology; as many as three self-administered surveys are mailed to mothers in the sample, and non-responders are followed up with a telephone interview. The first survey is typically mailed 2–3 months after delivery to allow for collection of information about postpartum maternal and infant experiences. Self-reported survey data are linked to selected birth certificate data and weighted for sample design, nonresponse, and noncoverage to create the PRAMS analysis data sets. Additional details regarding the PRAMS methodology have been described elsewhere (13).


Validity of specific questions is addressed through pretesting. New questions are tested through cognitive interviewing, in which respondents are asked to describe their understanding of the question's meaning and how they arrived at their response. On the basis of the results of the cognitive testing, questions are revised. A second round of testing involves administering the questionnaire to respondents, who are asked to complete it and provide written feedback. Before the next revision cycle, questions are evaluated for item nonresponse, write-in responses, and whether respondents correctly followed skip patterns. Questions that fare poorly in these evaluations are revised accordingly and pretested before being included in the questionnaire.

Data Analysis

This report includes data from 19 states (Alabama, Alaska, Arkansas, Colorado, Florida, Hawaii, Illinois, Louisiana, Maine, Nebraska, New Mexico, New York, North Carolina, Ohio, Oklahoma, South Carolina, Utah, Washington, West Virginia) (Figure 1) that collected data on year 2000 births and achieved weighted response rates of at least 70%. The weighted response rate indicates the proportion of women sampled who completed a survey, adjusted for sample design. For one reporting area, data are not representative of the entire state: New York data are for upstate New York only and exclude New York City, which has an autonomous vital records agency. Each state's stratification variables, annual sample size, and weighted response rate (range: 72%–86%) are listed (Appendix).

Data are presented for four maternal behaviors and experiences that were self-reported on the survey. To assess folic acid consumption, multivitamin use (i.e., taking a multivitamin four or more times per week during the month before pregnancy) was measured. Most commonly available multivitamins contain 400 µg of folic acid, the recommended daily dose for women of childbearing age. Pregnancy-related complications were defined as having stayed in the hospital for ≥1 day for any of the following conditions: preterm labor; high blood pressure; edema; vaginal bleeding; abruptio placentae; placenta previa; severe nausea, vomiting, or dehydration; diabetes; kidney or bladder infection; premature rupture of membranes; or incompetent cervix or cerclage. The definition of these pregnancy complications might include the delivery hospitalization if the medical complication occurred at the time of delivery. Infant checkup was defined as a visit to or by a medical doctor or nurse within 1 week of hospital

FIGURE 1. States participating in the Pregnancy Risk Assessment Monitoring System (PRAMS), 2000



discharge. This indicator is reported only for infants who were discharged within 48 hours of delivery. Postpartum contraceptive use was defined as using any of the following birth control methods 2–8 months postpartum at the time of the survey: tubal ligation (tubes tied), vasectomy, pill, condoms, foam, intrauterine device, Norplant®, Depo-Provera®, or rhythm method.

The 2000 prevalence estimates are presented by state with associated standard errors and 95% confidence intervals (CI). Graphs accompany the tables. Prevalence estimates for 2000 also are presented by maternal sociodemographic characteristic and state.

The sociodemographic characteristics of age, race, Hispanic ethnicity, and education were taken from the birth certificate. Maternal age was grouped into four categories (<20 years, 20–24 years, 25–34 years, ≥35 years). Race was grouped into three categories (white, black, other). In Alaska, the other race category comprised primarily Alaska Natives. In New Mexico and Oklahoma, the other race category comprised primarily Native Americans. In the remaining 16 states, the other race category was composed primarily of Asians. Ethnicity was defined as Hispanic or not Hispanic. Education was grouped into three categories (less than high school, high school, more than high school). Medicaid status was self-reported on the survey. A Medicaid recipient was defined as someone who was receiving Medicaid just before the pregnancy or who used Medicaid to pay for prenatal care or delivery.

All tables in the report were produced by using weighted PRAMS data. Percentages and standard errors were calculated for the characteristic of interest by using PROC CROSSTAB in SUDAAN (14). The 95% confidence intervals were computed by using the formula $CI = \text{percentage} \pm (1.96 \times \text{standard error})$. The number of respondents was the number of mothers who answered a particular question. All missing observations were excluded. An estimate is noted in the tables when the percentage of missing values is ≥10%. Because estimates based on small samples are imprecise and might be biased, estimates for which the number of respondents was <60 are noted in the tables that present data by sociodemographic characteristic. Estimates for which the number of respondents was <30 are not reported. The chi square test was used to identify statistically significant associations between sociodemographic variables and the indicators for each state. For age and education, logistic regression was performed in addition to the chi square test to assess linear relationships with each indicator. In cases in which the chi-square test indicated a significant association for race, an additional chi-square test was performed with race collapsed into two categories (black and white/other).

Results

Multivitamin Use

In 2000, 25.0%–40.7% of women reported taking a multivitamin ≥ 4 times per week in the month before pregnancy (Table 1). The prevalence was lowest in Oklahoma and West Virginia and was highest in Maine (Figure 2). In all 19 states, prevalence of multivitamin use increased with increasing maternal age (Table 2). In 14 states, an association was noted between race and the prevalence of multivitamin use (Table 2). In 11 of these states (Alabama, Illinois, Louisiana, Nebraska, New York, North Carolina, Ohio, Oklahoma, Utah, Washington, West Virginia), black women were significantly less likely to report multivitamin use than were women in the white/other category. In 10 of the 16 states where adequate data regarding Hispanic populations were available (Arkansas, Colorado, Hawaii, Illinois, Nebraska, New Mexico, New York, North Carolina, Utah, Washington), non-Hispanic women were more likely than Hispanic women to report multivitamin use.

In all states, women with >12 years of education were significantly more likely than women with ≤ 12 years to use

TABLE 1. Prevalence of multivitamin use* ≥ 4 times per week during the month before pregnancy — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

State	No. of respondents	Multivitamin use (%) [†]	SE [§]	95% CI [§]
Alabama	1,560	25.9	1.4	23.1–28.6
Alaska	1,470	30.9	1.4	28.2–33.6
Arkansas	1,647	25.3	1.6	22.2–28.4
Colorado	2,171	35.3	1.3	32.7–37.9
Florida	2,049	28.6	1.5	25.6–31.6
Hawaii	2,514	35.9	1.1	33.8–38.0
Illinois	2,004	33.5	1.1	31.3–35.6
Louisiana	2,297	29.7	1.2	27.4–32.0
Maine	1,150	40.7	1.6	37.5–43.9
Nebraska	2,118	34.1	1.3	31.6–36.6
New Mexico	1,606	28.5	1.2	26.2–30.8
New York [¶]	1,252	35.8	1.7	32.5–39.2
North Carolina	1,829	29.6	1.4	26.8–32.3
Ohio	1,656	34.7	1.6	31.5–37.8
Oklahoma	1,990	25.0	1.5	21.9–28.0
South Carolina	1,627	32.7	1.9	29.0–36.3
Utah	1,649	31.3	1.5	28.3–34.2
Washington	1,580	35.1	1.7	31.8–38.4
West Virginia	1,310	25.0	1.5	22.1–27.8

* Multivitamin use is used as a measure of folic acid consumption.

[†] For 2000, the range was 25.0%–40.7%.

[§] SE: standard error, CI: confidence interval.

[¶] Data do not include New York City.

e xplore.

Trekking through medical and scientific literature on the Web can sometimes be a long journey – but not at MMWR Online.


Whether you're researching past CDC reports or looking for the latest updates on important medical topics, MMWR Online quickly guides you to the information you need, free of charge.

Log on to cdc.gov/mmwr and boldly discover more.

know what matters.



FIGURE 2. Prevalence of multivitamin use* ≥ 4 times per week during the month before pregnancy — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000



* Multivitamin use is used as a measure of folic acid consumption.

[†] Data do not include New York City.

multivitamins (Table 2). In all states, women receiving Medicaid were significantly less likely than those not receiving Medicaid to report multivitamin use.

Pregnancy-Related Complications

In 2000, the prevalence of pregnancy-related complications that required a hospital stay of ≥ 1 day ranged from 8.8% to 16.3% across 19 states (Table 3). The prevalence was lowest in Utah and highest in Louisiana (Figure 3). When examined by age group, the prevalence of pregnancy-related complications was significantly higher among younger women than older women in four states (Maine, Nebraska, North Carolina, and West Virginia) (Table 4). Associations between race and pregnancy-related complications were found in six states (Alaska, Arkansas, Illinois, New Mexico, North Carolina, and South Carolina). In two states (North Carolina and South Carolina), black women had a significantly higher prevalence of pregnancy-related complications than women in the white/other race category. Prevalence of pregnancy-related complications was lower among Hispanic women than non-Hispanic women in three (Alabama, Colorado, and Oklahoma) of the 16 states where data were available for Hispanic populations.

In three states (Louisiana, Maine, and Nebraska), the prevalence of pregnancy-related complications declined with increasing maternal education (Table 4). In eight of 19 states (Alaska, Illinois, Louisiana, Maine, Nebraska, North Carolina, Ohio, Washington), Medicaid recipients were more likely than women who did not receive Medicaid to have pregnancy-related complications.

Infant Checkup

In 2000, the prevalence of infant checkups within 1 week after hospital stay of ≤ 48 hours ranged from 51.5% to 88.6% in 19 states (Table 5). The lowest and highest prevalences were in Utah and Colorado, respectively (Figure 4).

Significant differences in prevalence of infant checkups by age, race, and ethnicity were seen infrequently. In only two of 19 states (Alaska and Nebraska) was infant checkup associated with maternal age. The direction of the association differed in these two states (Table 6). In four states (Alaska, Hawaii, Nebraska, and Utah), race was significantly associated with infant checkups. In Nebraska, black women had a significantly lower prevalence of infant checkup than women in the white/other race category. However, in Utah, black women were more likely to report infant checkups than were women in the white/other race category (Table 6). Differences in the prevalence of infant checkup differed by Hispanic ethnicity in three states (Colorado, Florida, and New York). In Colorado and Florida, Hispanic women were less likely than non-Hispanic women to report infant checkup. In New York, Hispanic women had a higher prevalence of infant checkups than did non-Hispanic women.

In four states (Alaska, Colorado, New Mexico, and North Carolina), the prevalence of infant checkups increased with increasing maternal education (Table 6). In eight states (Alabama, Florida, Hawaii, Illinois, Louisiana, Nebraska, Oklahoma, South Carolina), infant checkup was associated with Medicaid status, although the direction of association differed across states.

Postpartum Contraceptive Use

In 2000, the prevalence of postpartum contraceptive use among women in 19 states who delivered a live infant ranged from 77.9% to 89.9% (Table 7). Prevalence was lowest in Hawaii and highest in North Carolina (Figure 5).

Use of postpartum contraception decreased significantly with age in only one state, Hawaii (Table 8). In five states (Alaska, Hawaii, Nebraska, Utah, and Washington), postpartum contraceptive use was associated with race (Table 8). In only one state (Alaska), black women were significantly more likely to report postpartum contraceptive use than were women

TABLE 2. Prevalence of multivitamin use* ≥ 4 times per week during the month before pregnancy, by selected sociodemographic characteristics — 19 states, Pregnancy Risk Monitoring System, (PRAMS), 2000†

Characteristic	Alabama		Alaska		Arkansas		Colorado		Florida		Hawaii		Illinois		Louisiana		Maine		Nebraska		
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	
Age group (yrs)																					
<20	13.4	(± 5.2)	15.4	(6.4)	17.7	(± 6.5)	14.1	(± 6.0)	14.1	(± 3.5)	16.9	(± 4.5)	14.8	(± 5.0)	18.9	(± 5.2)	14.8	(± 8.1)	12.4	(± 5.0)	
20–24	15.1	(± 3.9)	21.1	(4.5)	14.2	(± 4.1)	19.4	(± 4.4)	17.4	(± 5.0)	22.9	(± 3.6)	16.7	(± 3.6)	23.2	(± 3.9)	27.9	(± 6.1)	17.6	(± 4.0)	
25–34	37.1	(± 4.6)	36.7	(4.1)	33.9	(± 5.1)	43.1	(± 3.7)	33.9	(± 4.8)	40.6	(± 3.2)	40.0	(± 3.1)	35.9	(± 3.6)	47.8	(± 4.4)	42.5	(± 3.6)	
≥ 35	33.6	(± 12.4)	42.7	(8.0)	38.4	(± 13.9)	54.0	(± 7.4)	44.9	(± 9.1)	53.3	(± 5.5)	51.9	(± 6.1)	43.1	(± 8.3)	53.3	(± 8.7)	48.1	(± 7.9)	
Race																					
White	29.4	(± 3.5)	34.7	(± 3.9)	26.9	(± 3.5)	36.1	(± 2.7)	29.6	(± 3.8)	43.1	(± 4.6)	36.8	(± 2.5)	32.9	(± 3.0)	41.1	(± 3.2)	35.4	(± 2.8)	
Black	18.2	(± 4.3)	20.8 [§]	(± 12.1)	19.2	(± 6.9)	26.6	(± 13.5)	24.8	(± 4.2)	28.6 [§]	(± 13.5)	19.1	(± 4.3)	25.3	(± 3.7)	¶	¶	19.2	(± 3.7)	
Other	¶	¶	23.5	(± 3.4)	22.5 [§]	(± 19.2)	19.7	(± 10.7)	34.8 [§]	(± 20.0)	33.8	(± 2.4)	37.9	(± 12.7)	28.8 [§]	(± 17.6)	¶	¶	27.9	(± 5.0)	
Hispanic ethnicity																					
Yes	33.6 [§]	(± 20.8)	28.6	(± 12.0)	11.0	(± 8.0)	19.6	(± 4.4)	24.7	(± 5.9)	27.7	(± 4.7)	22.3	(± 4.2)	32.2 [§]	(± 17.1)	¶	¶	19.7	(± 3.3)	
No	25.6	(± 2.7)	31.3	(± 2.9)	26.3	(± 3.2)	41.4	(± 3.0)	30.0	(± 3.5)	37.2	(± 2.3)	36.7	(± 2.5)	29.6	(± 2.3)	40.6	(± 3.2)	35.6	(± 2.8)	
Education (yrs)																					
<12	14.0	(± 4.6)	23.1	(± 6.7)	14.3	(± 5.2)	18.6	(± 5.2)	18.3	(± 5.4)	23.4	(± 6.0)	20.4	(± 4.2)	24.9	(± 5.0)	16.4	(± 7.7)	13.1	(± 3.1)	
12	18.6	(± 4.2)	23.3	(± 3.8)	18.3	(± 4.2)	20.6	(± 4.0)	18.8	(± 4.4)	29.1	(± 3.1)	20.3	(± 3.4)	24.8	(± 3.6)	24.8	(± 4.7)	22.9	(± 4.3)	
>12	37.2	(± 4.7)	41.3	(± 4.6)	37.9	(± 5.6)	50.8	(± 3.7)	39.5	(± 4.9)	44.5	(± 3.2)	47.4	(± 3.3)	36.8	(± 3.7)	58.5	(± 4.4)	45.3	(± 3.6)	
Medicaid recipient**																					
No	35.7	(± 4.4)	38.5	(± 4.0)	37.6	(± 4.9)	43.9	(± 3.2)	36.6	(± 4.3)	40.2	(± 2.6)	43.9	(± 2.9)	38.1	(± 3.4)	51.8	(± 4.1)	44.1	(± 3.4)	
Yes	15.6	(± 3.2)	21.9	(± 3.4)	11.9	(± 3.0)	18.1	(± 3.7)	16.3	(± 3.5)	25.5	(± 3.4)	18.0	(± 2.9)	22.0	(± 3.1)	22.7	(± 4.6)	16.5	(± 3.0)	

TABLE 2. (Continued) Prevalence of multivitamin use* ≥ 4 times per week during the month before pregnancy, by selected sociodemographic characteristics — 19 states, Pregnancy Risk Monitoring System, (PRAMS), 2000†

Characteristic	New Mexico		New York††		North Carolina		Ohio		Oklahoma		South Carolina		Utah		Washington		West Virginia				
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)			
Age group (yrs)																					
<20	15.7	(± 4.5)	14.2	(± 8.7)	12.9	(± 5.7)	17.6	(± 6.5)	11.1	(± 5.9)	25.5	(± 8.6)	21.9	(± 11.4)	12.7	(± 7.3)	12.6	(± 3.4)			
20–24	17.4	(± 3.5)	16.2	(± 6.3)	16.1	(± 4.3)	19.4	(± 5.4)	19.0	(± 5.2)	20.9	(± 5.9)	24.2	(± 4.9)	21.1	(± 6.1)	17.4	(± 4.5)			
25–34	38.8	(± 3.8)	41.6	(± 4.6)	40.1	(± 4.2)	40.9	(± 4.6)	33.6	(± 4.8)	42.1	(± 5.8)	34.6	(± 4.1)	40.0	(± 4.7)	32.9	(± 4.8)			
≥ 35	45.3	(± 8.1)	50.7	(± 7.8)	36.2	(± 8.5)	57.4	(± 8.9)	21.0	(± 8.4)	37.9	(± 11.6)	43.2	(± 9.6)	52.0	(± 9.1)	36.4	(± 12.1)			
Race																					
White	29.0	(± 2.5)	37.6	(± 3.6)	33.2	(± 3.3)	38.0	(± 3.7)	27.6	(± 3.5)	35.9	(± 4.6)	31.9	(± 3.1)	36.7	(± 3.9)	25.7	(± 2.9)			
Black	¶	¶	17.3	(± 9.0)	20.0	(± 5.0)	19.0	(± 4.0)	16.0	(± 8.2)	26.5	(± 6.2)	21.0	(± 6.0)	21.8	(± 4.9)	6.6 [§]	(± 6.6)			
Other	27.2	(± 6.3)	44.1 [§]	(± 18.5)	15.7 [§]	(± 12.8)	25.4 [§]	(± 19.0)	15.2	(± 7.1)	¶	¶	21.2	(± 3.7)	28.6	(± 4.1)	¶	¶			
Hispanic ethnicity																					
Yes	21.6	(± 3.0)	23.8	(± 10.4)	20.6	(± 8.1)	¶	¶	15.5	(± 9.8)	28.9 [§]	(± 19.0)	18.9	(± 7.4)	21.9	(± 4.9)	¶	¶			
No	35.6	(± 3.4)	36.9	(± 4.0)	30.7	(± 2.9)	34.6	(± 3.2)	25.8	(± 3.2)	32.9	(± 3.8)	33.3	(± 3.2)	37.9	(± 3.9)	24.9	(± 2.8)			
Education (yrs)																					
<12	20.1	(± 4.2)	18.6	(± 8.2)	14.0	(± 4.5)	20.7	(± 7.0)	13.1	(± 5.4)	28.2	(± 7.9)	20.1	(± 7.8)	15.1	(± 5.1)	12.7	(± 4.8)			
12	22.1	(± 3.5)	28.7	(± 5.7)	21.5	(± 4.4)	23.6	(± 4.8)	21.0	(± 5.0)	24.1	(± 5.4)	27.1	(± 5.2)	19.6	(± 5.6)	17.5	(± 3.8)			
>12	43.3	(± 4.1)	45.0	(± 4.6)	43.8	(± 4.4)	46.2	(± 4.6)	33.5	(± 4.9)	43.5	(± 6.1)	36.8	(± 4.0)	47.9	(± 4.9)	38.5	(± 5.2)			
Medicaid recipient**																					
No	41.4	(± 3.7)	42.2	(± 4.0)	42.4	(± 4.1)	41.7	(± 3.9)	32.8	(± 4.4)	44.1	(± 5.7)	34.9	(± 3.5)	41.3	(± 4.2)	36.9	(± 4.8)			
Yes	18.2	(± 2.7)	19.5	(± 5.7)	16.8	(± 3.3)	17.9	(± 4.7)	15.8	(± 3.9)	22.8	(± 4.6)	22.7	(± 5.2)	20.7	(± 4.9)	15.8	(± 3.2)			

* Multivitamin use is used as a measure of folic acid consumption.

† Values are expressed as percentage of respondents using multivitamins $\pm 95\%$ confidence interval (CI).

§ Prevalence might be unreliable because number of respondents was < 60 .

¶ Prevalence was not reported because number of respondents was < 30 .

** A mother who reported that she was receiving Medicaid when she became pregnant or that Medicaid paid for her prenatal care or delivery.

†† Data do not include New York City.

in the white/other race category. Hispanic women in Hawaii were significantly more likely than non-Hispanic women to report postpartum birth control use (Table 8). In Utah, Hispanic women were significantly less likely than non-Hispanic women to report postpartum birth control use.

Postpartum contraceptive use increased with increasing maternal education in six states (Arkansas, Louisiana, Nebraska, Oklahoma, South Carolina, and West Virginia). Postpartum contraceptive use was associated with Medicaid status in three

states (Arkansas, Louisiana, and Oklahoma). Medicaid recipients were less likely than women who did not receive Medicaid to report postpartum contraceptive use (Table 8).

Discussion

Prevalence of the four indicators examined in this report varied among particular subpopulations of women. State-to-state variations also were seen in the prevalence of these

TABLE 3. Prevalence of pregnancy-related complications* that required a hospital stay of ≥ 1 day — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

State	No. of respondents	Complications (%) [†]	SE [§]	95% CI [§]
Alabama	1,560	13.0	1.0	11.1–14.9
Alaska	1,476	11.1	0.8	9.5–12.7
Arkansas	1,651	14.0	1.2	11.7–16.4
Colorado	2,165	10.7	0.8	9.2–12.2
Florida	2,032	12.2	1.0	10.3–14.1
Hawaii	2,471	9.2	0.6	8.0–10.4
Illinois	1,996	11.7	0.7	10.3–13.1
Louisiana	2,288	16.3	0.9	14.5–18.2
Maine	1,146	12.2	1.0	10.2–14.2
Nebraska	2,114	10.4	0.8	8.8–12.0
New Mexico	1,606	13.4	0.8	11.8–15.0
New York [¶]	1,254	11.3	1.1	9.3–13.4
North Carolina	1,825	13.1	0.9	11.2–14.9
Ohio	1,655	13.2	1.1	11.1–15.3
Oklahoma	1,985	12.0	1.1	9.9–14.2
South Carolina	1,612	14.8	1.3	12.3–17.4
Utah	1,646	8.8	0.9	7.1–10.5
Washington	1,587	11.3	1.1	9.1–13.5
West Virginia	1,300	15.1	1.1	13.0–17.2

* Pregnancy-related complications are defined as any of the following conditions: preterm labor; high blood pressure; edema; vaginal bleeding; abruptio placentae; placenta previa; severe nausea, vomiting, or dehydration; diabetes; kidney or bladder infection; premature rupture of membranes; or incompetent cervix or cerclage.

[†] For 2000, the range was 8.8%–16.3%.

[§] SE: standard error, CI: confidence interval.


[¶] Data do not include New York City.

indicators. Variations across states may be attributable to population differences in sociodemographic characteristics, differences in state and local policies, and variations in the availability of and access to health-care services.

Multivitamin Use

Increased folic acid consumption before conception and in early pregnancy reduces the incidence of neural tube defects and can also reduce the incidence of certain congenital heart defects (1,15–16). Congenital anomalies are the leading cause of infant death, causing 5,743 deaths, or 20.5% of all infant deaths, in 2000 (17). Neural tube defects alone caused 419 deaths (17).

In 1992, the U.S. Public Health Service recommended that all women of childbearing age consume 400 μg of folic acid daily (18). In 1998, the Food and Drug Administration required enriched cereal grain products to be fortified with folic acid. The *Healthy People 2010* goal is for 80% of non-pregnant women aged 15–44 years to consume at least 400 μg of folic acid each day from fortified foods or dietary supplements (12). Most commonly available multivitamins contain 400 μg of folic acid. In 2000, PRAMS began asking women if they took a multivitamin in the month before they became

FIGURE 3. Prevalence of pregnancy-related complications* that required a hospital stay of ≥ 1 day — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

* Pregnancy-related complications are defined as any of the following conditions: preterm labor; high blood pressure; edema; vaginal bleeding; abruptio placentae; placenta previa; severe nausea, vomiting, or dehydration; diabetes; kidney or bladder infection; premature rupture of membranes; or incompetent cervix or cerclage.

[†] Data do not include New York City.

pregnant. However, PRAMS does not capture folic acid consumption through other means (e.g., fortified foods).

Knowledge of these recommendations and of the benefits of folic acid consumption has spread slowly among childbearing women. In 2002, a March of Dimes national survey found that 75% of women had heard of folic acid, and 14% knew that folic acid helps prevent birth defects, but only 34% of women took a vitamin supplement containing folic acid (19). PRAMS data (25.0%–40.7% of women taking multivitamins) are consistent with the March of Dimes findings.

PRAMS data indicate that the *Healthy People 2010* objective for folic acid consumption, as measured by multivitamin use, is not being met in these states. State health departments can use these data to target campaigns promoting multivitamin use to populations in which folic acid consumption is lower than recommended (e.g., younger women, those with less education, and Medicaid recipients). States can also use PRAMS data as a benchmark for tracking progress toward the *Healthy People 2010* goal.

TABLE 4. Prevalence of pregnancy-related complications* that required a hospital stay of ≥ 1 day, by selected sociodemographic characteristics — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000†

Characteristic	Alabama		Alaska		Arkansas		Colorado		Florida		Hawaii		Illinois		Louisiana		Maine		Nebraska		
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	
Age group (yrs)																					
<20	15.7	(±5.4)	11.2	(±5.2)	14.4	(±5.4)	13.1	(±5.3)	13.9	(±3.2)	13.1	(±3.8)	16.8	(±5.1)	18.5	(±4.8)	22.2	(±9.3)	14.9	(±5.6)	
20–24	11.8	(±3.0)	12.3	(±3.1)	15.8	(±4.3)	12.1	(±3.2)	13.7	(±4.1)	8.9	(±2.2)	12.7	(±3.2)	18.5	(±3.5)	16.1	(±4.8)	13.6	(±3.6)	
25–34	12.9	(±2.8)	9.2	(±2.1)	12.6	(±3.4)	9.3	(±2.0)	12.1	(±3.0)	8.3	(±1.8)	10.6	(±1.9)	14.4	(±2.6)	10.4	(±2.5)	8.9	(±2.1)	
≥ 35	12.9	(±7.1)	15.3	(±5.3)	14.2	(±8.8)	11.3	(±3.9)	8.3	(±4.0)	9.6	(±3.2)	9.5	(±3.3)	14.1	(±5.5)	5.1	(±2.4)	7.0	(±3.8)	
Race																					
White	12.5	(±2.3)	9.4	(±2.1)	13.5	(±2.5)	10.2	(±1.5)	11.2	(±2.4)	10.5	(±2.9)	11.2	(±1.6)	14.9	(±2.2)	12.1	(±2.0)	10.3	(±1.8)	
Black	13.5	(±3.3)	15.5 [§]	(±9.1)	16.9	(±6.6)	20.6	(±11.0)	15.2	(±3.1)	17.3 [§]	(±11.7)	14.6	(±3.5)	18.6	(±3.2)	¶	¶	14.0	(±3.2)	
Other	¶	¶	13.9	(±2.3)	5.0 [§]	(±4.2)	12.1	(±9.3)	14.9 [§]	(±12.7)	8.5	(±1.3)	5.2	(±5.3)	8.7 [§]	(±10.1)	¶	¶	9.2	(±2.2)	
Hispanic ethnicity																					
Yes	3.3 [§]	(±5.8)	11.4	(±7.3)	8.4	(±6.8)	8.0	(±2.6)	10.6	(±3.7)	10.4	(±3.1)	10.7	(±3.0)	13.8 [§]	(±12.1)	¶	¶	11.8	(±2.7)	
No	13.4	(±1.9)	11.0	(±1.7)	14.3	(±2.4)	11.8	(±1.8)	12.8	(±2.2)	9.0	(±1.3)	11.9	(±1.6)	16.4	(±1.9)	12.3	(±2.0)	10.7	(±1.8)	
Education (yrs)																					
<12	13.0	(±3.9)	9.5	(±3.7)	11.8	(±4.5)	8.8	(±3.2)	13.8	(±4.1)	10.8	(±3.7)	12.8	(±3.4)	19.2	(±4.4)	16.7	(±7.5)	13.2	(±3.9)	
12	14.0	(±3.4)	11.6	(±2.5)	18.0	(±4.3)	14.3	(±3.5)	10.7	(±2.9)	9.2	(±1.8)	13.8	(±2.8)	18.0	(±3.1)	14.6	(±3.7)	12.8	(±3.5)	
>12	12.4	(±2.8)	10.5	(±2.5)	11.3	(±3.3)	9.7	(±1.9)	12.6	(±3.1)	8.8	(±1.8)	10.0	(±1.8)	13.2	(±2.5)	9.4	(±2.2)	8.6	(±2.0)	
Medicaid recipient**																					
No	12.4	(±2.7)	8.5	(±2.0)	11.8	(±2.8)	11.7	(±2.0)	11.1	(±2.5)	8.7	(±1.5)	10.3	(±1.7)	12.9	(±2.3)	8.7	(±2.0)	7.5	(±1.8)	
Yes	13.7	(±2.6)	14.1	(±2.5)	16.4	(±3.7)	8.7	(±2.1)	13.9	(±3.0)	10.3	(±2.1)	13.7	(±2.4)	19.5	(±2.8)	17.9	(±4.0)	15.5	(±3.1)	

TABLE 4. (Continued) Prevalence of pregnancy-related complications* that required a hospital stay of ≥ 1 day, by selected sociodemographic characteristics — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000†

Characteristic	New Mexico		New York ^{††}		North Carolina		Ohio		Oklahoma		South Carolina		Utah		Washington		West Virginia				
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)			
Age group (yrs)																					
<20	15.7	(±4.1)	16.9	(±9.1)	22.0	(±7.0)	14.7	(±5.6)	11.8	(±5.7)	14.8	(±6.5)	8.0	(±6.8)	12.1	(±7.2)	21.8	(±4.1)			
20–24	12.3	(±3.0)	13.0	(±5.4)	14.9	(±3.9)	15.9	(±4.6)	11.2	(±3.6)	17.1	(±5.1)	9.9	(±3.3)	13.4	(±5.1)	16.2	(±4.1)			
25–34	12.6	(±2.4)	9.3	(±2.4)	10.7	(±2.3)	11.7	(±2.9)	13.5	(±3.4)	14.1	(±3.7)	8.8	(±2.3)	10.3	(±2.9)	12.4	(±3.1)			
≥ 35	16.6	(±5.8)	12.3	(±4.8)	8.3	(±3.9)	12.2	(±5.6)	7.6	(±5.3)	11.7	(±6.6)	5.8	(±4.3)	11.5	(±6.1)	13.0	(±7.2)			
Race																					
White	14.3	(±1.8)	10.4	(±2.1)	11.9	(±2.1)	12.7	(±2.4)	11.6	(±2.4)	13.0	(±3.0)	8.8	(±1.8)	10.9	(±2.6)	14.6	(±2.1)			
Black	¶	¶	21.5	(±9.1)	17.5	(±4.3)	16.0	(±3.3)	9.8	(±4.7)	18.9	(±5.0)	8.7	(±3.6)	12.4	(±3.9)	23.7 [§]	(±13.7)			
Other	8.2	(±3.4)	8.2 [?]	(±11.0)	5.5 [§]	(±3.0)	12.1 [§]	(±13.3)	18.1	(±8.0)	¶	¶	8.8	(±2.5)	9.3	(±2.5)	¶	¶			
Hispanic ethnicity																					
Yes	14.5	(±2.4)	12.6	(±7.1)	10.7	(±5.9)	¶	¶	5.3	(±4.7)	6.8 [§]	(±9.3)	6.8	(±5.1)	12.2	(±4.0)	¶	¶			
No	12.3	(±2.2)	11.9	(±2.5)	13.2	(±2.0)	13.2	(±2.1)	12.7	(±2.3)	15.0	(±2.6)	9.0	(±1.8)	10.6	(±2.5)	15.1	(±2.1)			
Education (yrs)																					
<12	11.4	(±3.0)	14.6	(±7.0)	16.2	(±4.6)	15.0	(±5.7)	9.8	(±4.2)	13.9	(±5.5)	10.3	(±5.5)	10.2	(±4.4)	14.1	(±4.2)			
12	15.4	(±2.9)	11.3	(±3.6)	11.6	(±3.0)	13.1	(±3.3)	13.6	(±3.9)	17.3	(±4.5)	8.2	(±2.9)	12.9	(±4.8)	17.1	(±3.5)			
>12	13.0	(±2.7)	10.1	(±2.5)	12.3	(±2.6)	12.6	(±3.0)	12.5	(±3.3)	13.0	(±3.7)	8.9	(±2.3)	9.9	(±2.9)	13.7	(±3.4)			
Medicaid recipient**																					
No	12.3	(±2.3)	10.5	(±2.3)	8.8	(±2.0)	11.2	(±2.3)	10.7	(±2.7)	12.1	(±3.4)	7.7	(±1.9)	8.7	(±2.5)	14.1	(±3.2)			
Yes	14.3	(±2.3)	13.6	(±4.5)	17.3	(±3.1)	18.0	(±4.3)	13.6	(±3.4)	17.2	(±3.8)	11.4	(±3.6)	17.2	(±4.6)	15.9	(±2.8)			

* Pregnancy-related complications are defined as any of the following conditions: preterm labor; high blood pressure; edema; vaginal bleeding; abruptio placentae; placenta previa; severe nausea, vomiting, or dehydration; diabetes; kidney or bladder infection; premature rupture of membranes; or incompetent cervix or cerclage.

† Values are expressed as percentage of respondents with complication $\pm 95\%$ confidence interval (CI).

‡ Prevalence might be unreliable because number of respondents was < 60 .

¶ Prevalence was not reported because number of respondents was < 30 .

** A mother who reported that she was receiving Medicaid when she became pregnant or that Medicaid paid for her prenatal care or delivery.

†† Data do not include New York City.

Pregnancy-Related Complications

Pregnancy-related complications contribute to maternal, fetal, and infant mortality and morbidity (2,20). These severe complications continue to be a priority area for *Healthy People 2010*, which includes objectives that address reducing maternal complications during pregnancy (12). Hospitalization rates for pregnancy-related complications have been the primary means for measuring maternal morbidity (21). Monitoring

of severe pregnancy-related complications is crucial in assessing maternal morbidity and mortality.


Infant Checkup

Length of hospital stay after childbirth has decreased dramatically in the last 30 years because of social and financial factors (3–4,22). Since the early 1990s, ongoing debate has occurred regarding the safety of early hospital discharge of

TABLE 5. Prevalence of infant checkups within 1 week of hospital discharge* — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

State	No. of respondents	Infant checkup (%) [†]	SE [§]	95% CI [§]
Alabama	653	65.7	2.1	61.6–69.8
Alaska	826	73.9	1.6	70.8–76.9
Arkansas	876	65.4	2.1	61.2–69.7
Colorado	1,237	88.6	1.1	86.4–90.7
Florida	823	77.9	1.9	74.2–81.6
Hawaii	1,564	79.6	1.2	77.3–81.9
Illinois	1,139	76.9	1.3	74.4–79.4
Louisiana	871	69.4	1.6	66.2–72.5
Maine	564	78.6	1.8	75.2–82.1
Nebraska	1,280	75.7	1.4	72.9–78.5
New Mexico	1,017	84.9	1.2	82.6–87.2
New York [¶]	549	79.0	1.9	75.3–82.7
North Carolina	824	79.8	1.6	76.7–82.8
Ohio	768	78.2	1.8	74.6–81.7
Oklahoma	813	67.0	2.2	62.7–71.4
South Carolina	445	75.1	2.4	70.5–79.7
Utah	998	51.5	2.0	47.6–55.4
Washington	1,114	87.3	1.4	84.5–90.0
West Virginia	700	73.8	1.9	70.1–77.5

* For those discharged within 48 hours.

[†] For 2000, the range was 51.5%–88.6%.[§] SE: standard error, CI: confidence interval.[¶] Data do not include New York City.**FIGURE 4. Prevalence of infant checkups within 1 week of hospital discharge* — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000**

* Among those discharged within 48 hours.

[†] Data do not include New York City.

mothers and newborns. In the mid-1990s, concern about harm to newborns as a result of early postpartum hospital discharge resulted in laws to establish minimum hospital stay of 48 hours after a vaginal delivery (22). Guidelines of the American Academy of Pediatrics (AAP) and American College of Obstetrics and Gynecology (ACOG) recommend at least 48 hours of postpartum hospitalization (23,24). AAP, ACOG, and other national and international authorities also recommend that newborns are followed up within the first week of birth in cases of early hospital discharge (3,22).

Numerous serious medical conditions become apparent 24–72 hours after birth. These include sepsis, congenital heart disease, jaundice, and other problems that may require evaluation and treatment (4,22). Although certain studies demonstrate reductions in hospital and patient costs, improvement in patient satisfaction, and promotion of family bonding when mothers and newborns are discharged earlier (4,22,25), the majority of studies conclude that early hospital discharge can lead to problems if appropriate follow-up is not performed (4,5,22).

In 2000, PRAMS began collecting infant follow-up data, which complement the infant early discharge data collected in previous years. These data indicate that as a woman's education increased, so did the likelihood of having her infant followed up within 1 week after being discharged within 48 hours of delivery. PRAMS data can be useful for assessing the proportion of newborns receiving follow-up in the first week after early discharge. This information can be used to conservatively monitor the level of adherence to the AAP and ACOG guidelines, which recommend follow-up within 48 hours after discharge.

Postpartum Contraceptive Use

Infants born to women who became pregnant 18–59 months after a prior birth have been found to be at lower risk of dying, being born preterm, being small for gestational age, or having low birthweight compared with infants born following an inter-pregnancy interval of <6 months or >59 months (26–30). Postpartum contraceptive use is critical in preventing pregnancy shortly after childbirth. Studies that have examined the efficacy and appropriateness of various contraceptive methods during the postpartum period have indicated that certain

TABLE 6. Prevalence of infant checkups within 1 week of hospital discharge,* by selected demographic characteristics — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000†

Characteristic	Alabama		Alaska		Arkansas		Colorado		Florida		Hawaii		Illinois		Louisiana		Maine		Nebraska		
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	
Age group (yrs)																					
<20	75.1	(±9.6)	62.4	(±11.1)	64.6	(±9.8)	87.7	(±6.5)	77.5	(±5.9)	83.1	(±5.7)	72.3	(±8.6)	71.0	(±8.7)	79.9§	(±11.9)	84.5	(±7.1)	
20–24	63.1	(±7.1)	69.2	(±6.1)	66.5	(±7.0)	87.5	(±4.3)	72.6	(±8.0)	75.3	(±4.5)	73.4	(±5.7)	69.6	(±5.8)	78.7	(±7.1)	80.7	(±5.2)	
25–34	64.0	(±6.2)	78.2	(±4.1)	65.2	(±6.5)	88.8	(±2.9)	78.8	(±5.5)	80.7	(±3.4)	79.1	(±3.3)	69.2	(±4.5)	77.8	(±4.7)	74.1	(±3.9)	
≥35	70.9§	(±16.4)	76.5	(±8.3)	63.9§	(±17.9)	90.2	(±6.3)	85.8	(±8.9)	80.7	(±6.1)	78.0	(±6.6)	66.2	(±12.0)	81.1	(±9.3)	64.6	(±9.8)	
Race																					
White	65.4	(±4.8)	81.1	(±3.9)	65.2	(±4.6)	88.4	(±2.2)	78.1	(±4.5)	66.3	(±5.4)	78.1	(±2.8)	68.5	(±3.8)	78.7	(±3.5)	76.1	(±3.1)	
Black	67.1	(±7.9)	¶	¶	69.8	(±10.7)	92.2§	(±11.7)	76.9	(±6.1)	¶	¶	72.5	(±7.0)	70.7	(±5.8)	¶	¶	65.6	(±6.3)	
Other	¶	¶	58.4	(±4.7)	¶	¶	88.7§	(±10.6)	¶	¶	84.7	(±2.4)	69.8§	(±14.0)	¶**	¶	¶	¶	76.6	(±4.6)	
Hispanic ethnicity																					
Yes	¶	¶	83.8§	(±12.8)	72.1§	(±16.7)	81.5	(±5.8)	66.8	(±9.5)	76.7	(±5.9)	74.6	(±5.6)	¶	¶	¶	¶	80.0	(±4.4)	
No	64.9	(±4.2)	73.8	(±3.2)	65.1	(±4.4)	91.1	(±2.0)	81.0	(±3.8)	80.1	(±2.5)	77.6	(±2.8)	69.8	(±3.2)	78.5	(±3.5)	75.4	(±3.1)	
Education, years																					
<12	72.3	(±8.8)	69.2	(±9.1)	64.6	(±8.8)	83.2	(±6.5)	72.1	(±8.9)	89.3	(±4.8)	75.3	(±6.2)	69.3	(±7.5)	81.6	(±10.4)	80.5	(±5.8)	
12	66.4	(±7.0)	69.1	(±4.8)	65.3	(±6.9)	86.1	(±4.4)	75.8	(±6.5)	74.9	(±3.9)	76.5	(±4.7)	72.4	(±5.1)	74.4	(±6.0)	78.5	(±5.2)	
>12	62.6	(±6.1)	80.3	(±4.6)	65.6	(±6.7)	91.6	(±2.3)	81.3	(±5.2)	81.0	(±3.2)	77.5	(±3.4)	67.4	(±4.7)	80.7	(±4.6)	73.2	(±3.9)	
Medicaid recipient††																					
No	61.2	(±6.0)	73.1	(±4.4)	65.0	(±5.9)	90.1	(±2.3)	81.5	(±4.5)	77.6	(±2.9)	80.0	(±3.0)	66.3	(±4.3)	79.4	(±4.2)	73.5	(±3.7)	
Yes	71.1	(5.5)	74.9	(±4.1)	65.9	(±6.0)	85.4	(±4.5)	71.4	(±6.4)	84.9	(±3.4)	72.1	(±4.5)	72.7	(±4.7)	77.2	(±6.2)	80.0	(±4.2)	

TABLE 6. (Continued) Prevalence of infant checkups within 1 week of hospital discharge,* by selected demographic characteristics — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000†

Characteristic	New Mexico		New York§§		North Carolina		Ohio		Oklahoma		South Carolina		Utah		Washington		West Virginia			
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)		
Age group (yrs)																				
<20	85.3	(±5.4)	81.4§	(±13.7)	75.8	(±9.7)	80.9	(±9.5)	67.2	(±12.4)	79.5	(±10.9)	55.0	(±16.1)	92.3	(±5.6)	72.9	(±6.1)		
20–24	82.9	(±4.3)	74.1	(±9.6)	77.1	(±6.4)	75.1	(±7.8)	64.7	(±8.1)	77.8	(±8.5)	56.6	(±6.8)	87.9	(±5.5)	79.9	(±6.0)		
25–34	85.4	(±3.4)	78.8	(±5.0)	82.3	(±4.0)	81.5	(±4.6)	68.0	(±6.2)	72.5	(±7.0)	49.3	(±5.3)	87.6	(±3.7)	70.5	(±5.9)		
≥35	89.6	(±6.9)	83.5	(±7.4)	78.5	(±10.2)	66.4	(±11.7)	70.2	(±15.1)	72.4§	(±14.8)	43.6	(±12.5)	81.6	(±8.9)	63.8§	(±17.3)		
Race																				
White	85.3	(±2.5)	78.9	(±4.0)	80.1	(±3.5)	78.7	(±4.0)	69.1	(±4.8)	73.6	(±5.5)	51.1	(±4.1)	87.2	(±3.2)	73.8	(±3.7)		
Black	¶**	¶	79.2§	(±13.7)	78.0	(±6.8)	77.9	(±6.0)	60.6	(±15.8)	78.4	(±9.0)	62.7	(±9.8)	85.0	(±5.5)	¶	¶		
Other	81.7	(±6.6)	¶	¶	¶	¶	¶	¶	58.1	(±13.9)	¶	¶	63.1	(±5.7)	88.7	(±3.3)	¶	¶		
Hispanic ethnicity																				
Yes	85.1	(±3.3)	92.5§	(±9.7)	73.5§	(±12.1)	¶	¶	49.9	(±17.7)	¶	¶	54.1	(±11.9)	84.0	(±5.5)	¶	¶		
No	84.6	(±3.2)	76.9	(±4.6)	80.5	(±3.2)	78.5	(±3.5)	68.5	(±4.5)	74.9	(±4.7)	51.1	(±4.1)	87.8	(±3.1)	73.6	(±3.7)		
Education (yrs)																				
<12	81.3	(±5.1)	74.0§	(±13.1)	73.3	(±7.4)	77.6	(±10.2)	61.6	(±10.5)	81.3	(±10.0)	52.4**	(±13.1)	85.9	(±6.6)	78.2	(±7.8)		
12	82.6	(±4.1)	74.8	(±7.3)	77.5	(±5.8)	79.0	(±6.1)	64.0	(±7.9)	76.0	(±7.5)	51.5	(±7.2)	82.8	(±6.3)	74.3	(±5.7)		
>12	89.8	(±3.1)	81.8	(±4.5)	84.5	(±3.9)	77.9	(±4.8)	73.4	(±5.9)	71.9	(±7.1)	51.7	(±5.0)	89.4	(±3.6)	71.8	(±5.9)		
Medicaid recipient††																				
No	87.3	(±3.2)	80.2	(±4.1)	82.1	(±4.0)	78.5	(±4.1)	71.2	(±5.5)	68.1	(±6.8)	52.3	(±4.5)	87.3	(±3.4)	72.7	(±5.6)		
Yes	82.9	(±3.3)	75.0	(±9.0)	77.3	(±4.8)	77.4	(±6.9)	61.8	(±7.1)	82.7	(±5.9)	49.4	(±7.5)	87.2	(±4.5)	74.7	(±4.8)		

* For those discharged within 48 hours.

† Values are expressed as percentage of respondents whose infants had checkups ±95% confidence interval (CI).

§ Prevalence might be unreliable because number of respondents was <60.

¶ Prevalence was not reported because number of respondents was <30.

** ≥10% of data missing.

†† A mother who reported that she was receiving Medicaid when she became pregnant or that Medicaid paid for her prenatal care or delivery.

§§ Data do not include New York City.

hormonal methods can affect breastfeeding by reducing the production of milk, and other methods should not be initiated until 4–8 weeks after delivery (31). However, safe and effective methods that can be used shortly after delivery have been identified. Recent research has indicated that Depo-Provera® injections are effective in preventing repeat pregnancies among postpartum adolescents (32–34). Other appropriate postpartum methods include vaginal rings, progestin-only pills and Copper T 380-A intrauterine devices (35).

PRAMS collects data regarding prevalence of contraceptive use following the birth of a live infant and reasons for not using contraception during the postpartum period (not reported here). Selected states also capture the type of contraceptives that a woman is using. These data can be helpful in informing policy and programs that are working toward the *Healthy People 2010* objective of reducing the number of births occurring within 24 months of a previous birth from the baseline measure of 11% to the target of 6%.

TABLE 7. Prevalence of postpartum contraceptive use* — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

State	No. of respondents	Contraceptive use (%) [†]	SE [§]	95% CI [§]
Alabama	1,561	88.5	1.0	86.5–90.5
Alaska	1,465	80.9	1.2	78.6–83.2
Arkansas	1,650	87.9	1.1	85.7–90.2
Colorado	2,150	87.7	0.9	85.9–89.4
Florida	2,014	85.8	1.2	83.5–88.1
Hawaii	2,480	77.9	1.0	76.0–79.8
Illinois	1,986	84.6	0.9	82.9–86.3
Louisiana	2,272	85.1	0.9	83.3–87.0
Maine	1,144	88.6	1.1	86.5–90.6
Nebraska	2,093	86.2	0.9	84.4–88.0
New Mexico	1,607	86.9	0.9	85.2–88.7
New York [¶]	1,247	84.0	1.3	81.4–86.7
North Carolina	1,818	89.9	0.9	88.1–91.7
Ohio	1,651	84.6	1.2	82.1–87.0
Oklahoma	1,985	85.4	1.3	82.8–87.9
South Carolina	1,597	87.1	1.3	84.4–89.7
Utah	1,629	88.4	1.0	86.3–90.4
Washington	1,576	88.8	1.1	86.7–91.0
West Virginia	1,293	88.6	1.0	86.6–90.7

* Postpartum contraceptive use is defined as using any of the following birth control methods at time of survey: tubal ligation, vasectomy, pill, condoms, foam, intrauterine device, Norplant[®], Depo-Provera[®], or rhythm.

[†] For 2000, the range was 77.9%–89.9%.

[§] SE: standard error, CI: confidence interval.

[¶] Data do not include New York City.


Limitations

Several limitations affect the data presented in this report. Because data are self-reported 2–8 months after delivery, responses might be subject to recall bias, particularly for behaviors and experiences that occurred before the pregnancy (e.g., folic acid consumption). Recall may also differ for the subset of women who experienced pregnancy complications or whose infants experienced health problems. PRAMS provides population-based data for each participating state; results are not generalizable to other states or to the United States as a whole. The associations between the indicators and age, race, ethnicity, education, and Medicaid status could all be a function of socioeconomic status. No controlling for confounding factors was done in this analysis, and additional research is needed to assess the effects of these factors when controlling for socioeconomic status. Finally, the associations between a specific indicator and demographic characteristic do not imply causality.

Conclusion

The health of mothers and their infants is affected by behaviors and experiences that occur before, during, and after pregnancy. This is the first report from PRAMS covering four indicators designed to capture these time periods. Certain sociodemographic groups of women (e.g., black women) were less likely to engage in protective behaviors such as multivitamin use, getting a postnatal checkup for their newborn infant, and postpartum contraceptive use. Pregnancy-related complications were experienced by different groups of women in different states. These data can be used to tailor the development of state-based programs, such as education initiatives and services for women at highest risk in each state.

A distinct feature of PRAMS is that it allows states to obtain population-based estimates to support their maternal and child health programs. In the past, states have used data from PRAMS to generate legislative support for maternal and child health programs. Legislature appropriation for unintended pregnancy, a 5-year funded state-wide smoking cessation campaign, and increased domestic violence screening for pregnant women

FIGURE 5. Prevalence of postpartum contraceptive use* — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

* Postpartum contraceptive use is defined as using any of the following birth control methods at time of survey: tubal ligation, vasectomy, pill, condoms, foam, intrauterine device, Norplant[®], Depo-Provera[®], or rhythm.

[†] Data do not include New York City.

TABLE 8. Prevalence of postpartum contraceptive use,* by selected sociodemographic characteristics — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000†

Characteristic	Alabama		Alaska		Arkansas		Colorado		Florida		Hawaii		Illinois		Louisiana		Maine		Nebraska	
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)
Age group (yrs)																				
<20	84.9	(±5.7)	81.5	(±6.3)	87.3	(±5.6)	88.5	(±4.8)	83.6	(±3.7)	82.4	(±4.3)	85.0	(±5.1)	83.0	(±4.8)	94.6	(±4.3)	83.7	(±5.7)
20–24	88.3	(±3.5)	83.5	(±4.1)	85.4	(±4.1)	87.7	(±3.9)	84.9	(±4.9)	81.0	(±3.5)	85.5	(±3.6)	84.0	(±3.5)	87.7	(±4.5)	85.5	(±3.7)
25–34	89.7	(±2.9)	81.4	(±3.3)	90.9	(±3.1)	90.1	(±2.2)	88.3	(±3.3)	78.6	(±2.8)	86.1	(±2.2)	86.8	(±2.6)	89.3	(±2.8)	86.7	(±2.4)
≥35	90.8	(±6.6)	74.0	(±7.1)	80.8	(±10.7)	77.0	(±6.3)	81.0	(±7.0)	68.6	(±5.3)	77.2	(±5.2)	85.2	(±6.0)	82.8	(±6.7)	87.4	(±5.1)
Race																				
White	88.7	(±2.5)	82.8	(±3.1)	88.4	(±2.4)	87.8	(±1.8)	85.9	(±2.8)	83.9	(±3.4)	84.5	(±1.9)	86.9	(±2.1)	89.0	(±2.1)	86.7	(±2.0)
Black	88.5	(±3.5)	90.4§	(±8.7)	86.4	(±5.7)	93.4	(±5.8)	86.2	(±3.2)	76.6§	(±13.4)	85.9	(±4.0)	83.3	(±3.2)	¶	¶	84.4	(±3.4)
Other	¶	¶	75.6	(±3.4)	82.1§	(±16.7)	79.8	(±12.1)	77.1§	(±18.0)	76.0	(±2.3)	79.1	(±10.8)	68.8§**	(±19.7)	¶	¶	78.8	(±3.2)
Hispanic ethnicity																				
Yes	¶	¶	74.1	(±12.0)	78.3	(±11.4)	86.0	(±4.0)	84.4	(±4.8)	84.4	(±3.8)	84.8	(±3.7)	87.6§	(±11.5)	¶	¶	84.0	(±3.1)
No	88.3	(±2.0)	81.5	(±2.3)	88.6	(±2.3)	88.3	(±1.9)	86.2	(±2.6)	76.8	(±2.1)	84.5	(±1.9)	85.1	(±1.9)	88.5	(±2.1)	86.7	(±2.0)
Education (yrs)																				
<12	87.8	(±4.3)	73.2	(±6.9)	81.6	(±5.8)	88.8	(±4.1)	82.5	(±5.0)	76.6	(±6.0)	84.7	(±4.0)	82.0	(±4.3)	85.3	(±7.2)	79.8	(±4.7)
12	89.9	(±3.2)	81.8	(±3.3)	88.5	(±3.5)	88.7	(±3.3)	85.6	(±4.0)	78.3	(±2.9)	86.9	(±2.9)	84.1	(±3.1)	90.6	(±3.1)	88.2	(±3.2)
>12	87.8	(±3.2)	82.3	(±3.6)	90.7	(±3.1)	87.0	(±2.4)	87.4	(±3.4)	77.7	(±2.8)	83.7	(±2.4)	87.9	(±2.5)	88.0	(±2.9)	86.9	(±2.4)
Medicaid recipient††																				
No	89.7	(±2.8)	81.7	(±3.2)	90.5	(±2.7)	87.9	(±2.1)	86.7	(±3.0)	78.8	(±2.3)	84.3	(±2.2)	88.4	(±2.3)	87.8	(±2.7)	86.6	(±2.3)
Yes	87.3	(±2.9)	80.0	(±3.2)	85.2	(±3.6)	87.2	(±3.3)	84.3	(±3.6)	75.7	(±3.5)	85.1	(±2.8)	82.1	(±2.8)	89.8	(±3.3)	85.5	(±2.8)

TABLE 8. (Continued) Prevalence of postpartum contraceptive use,* by selected sociodemographic characteristics — 19 states, Pregnancy Risk Assessment Monitoring System (PRAMS), 2000†

Characteristic	New Mexico		New York§§		North Carolina		Ohio		Oklahoma		South Carolina		Utah		Washington		West Virginia	
	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)	%	(CI)
Age group (yrs)																		
<20	82.7	(±4.7)	91.2	(±7.5)	92.5	(±4.5)	84.6	(±7.1)	79.2	(±8.0)	90.4	(±5.5)	87.1	(±8.4)	90.7	(±5.9)	85.2	(±3.7)
20–24	87.6	(±3.2)	82.2	(±6.9)	92.0	(±3.1)	82.7	(±5.3)	85.1	(±4.8)	81.0	(±5.9)	89.5	(±3.6)	87.0	(±4.8)	87.8	(±3.9)
25–34	89.2	(±2.4)	84.4	(±3.5)	88.9	(±2.7)	86.4	(±3.1)	86.6	(±3.6)	89.2	(±3.6)	89.2	(±2.7)	89.2	(±3.0)	90.1	(±3.0)
≥35	82.3	(±6.1)	81.4	(±6.2)	86.4	(±6.4)	80.9	(±7.5)	90.2	(±6.4)	90.0	(±7.1)	81.8	(±8.0)	89.0	(±5.3)	90.3	(±7.8)
Race																		
White	87.3	(±1.9)	83.6	(±2.9)	90.7	(±2.0)	85.3	(±2.8)	86.3	(±2.8)	86.7	(±3.3)	88.8	(±2.2)	90.1	(±2.5)	88.9	(±2.1)
Black	¶	¶	90.3	(±6.5)	87.8	(±4.0)	81.5	(±4.9)	79.2	(±9.4)	89.2	(±4.3)	85.1	(±5.3)	86.5	(±4.1)	90.1§	(±9.2)
Other	83.9	(±5.2)	81.9§	(±13.8)	86.9§	(±11.9)	79.1§	(±17.2)	88.7	(±7.1)	¶	¶	79.4	(±3.8)	80.2	(±3.6)	¶	¶
Hispanic ethnicity																		
Yes	88.5	(±2.4)	76.2	(±10.9)	89.2	(±6.2)	¶	¶	79.4	(±10.9)	83.7§	(±15.7)	79.6	(±8.5)	92.1	(±3.3)	¶	¶
No	85.2	(±2.6)	84.5	(±3.0)	90.0	(±1.9)	84.6	(±2.5)	85.7	(±2.7)	87.3	(±2.7)	89.6	(±2.0)	88.2	(±2.5)	88.8	(±2.0)
Education (yrs)																		
<12	85.6	(±3.7)	84.0	(±8.0)	89.9	(±3.9)	80.9	(±7.4)	77.1	(±7.0)	81.1	(±6.8)	80.3	(±7.8)	88.1	(±4.9)	87.3	(±4.7)
12	86.9	(±2.9)	86.4	(±4.3)	91.8	(±2.8)	86.1	(±3.9)	86.9	(±4.2)	86.7	(±4.4)	88.2	(±3.9)	86.8	(±4.8)	86.3	(±3.4)
>12	87.8	(±2.7)	82.8	(±3.6)	88.7	(±2.8)	84.9	(±3.3)	88.6	(±3.4)	90.7	(±3.5)	90.3	(±2.4)	89.7	(±2.9)	92.2	(±2.9)
Medicaid recipient††																		
No	88.1	(±2.4)	83.1	(±3.1)	89.8	(±2.5)	86.0	(±2.7)	88.4	(±3.0)	89.4	(±3.5)	89.0	(±2.3)	89.5	(±2.6)	87.8	(±3.3)
Yes	86.0	(±2.5)	86.4	(±5.0)	90.1	(±2.6)	81.1	(±5.1)	81.7	(±4.3)	85.0	(±3.9)	86.9	(±4.2)	87.2	(±3.9)	89.3	(±2.6)

* Postpartum contraceptive use is defined as using any of the following birth control methods at time of survey: tubal ligation, vasectomy, pill, condoms, foam, intrauterine device, Norplant®, Depo-Provera®, or rhythm.

† Values are expressed as percentage of respondents using contraceptives ±95% confidence interval (CI).

§ Prevalence might be unreliable because number of respondents was <60.

¶ Prevalence was not reported because number of respondents was <30.

** ≥10% of data missing.

†† A mother who reported that she was receiving Medicaid when she became pregnant or that Medicaid paid for her prenatal care or delivery.

§§ Data do not include New York City.

are just a few examples of how states interpret and use PRAMS data (36). By obtaining more years of data on the indicators in this report and by continuing monitoring of the prevalence and sociodemographic characteristics of women reporting these behaviors and experiences, states can help clarify patterns and direct appropriate prevention strategies.

Acknowledgments

The PRAMS Working Group: Alabama: Rhonda Stephens, M.P.H.; Alaska: Kathy Perham-Hester, M.P.H.; Arkansas: Gina Redford, M.A.P.; Colorado: Alyson Shupe, Ph.D.; Florida: Steven Wiersma, M.D.; Georgia: Tonya Johnson; Hawaii: Limin Song, M.P.H.; Illinois: Theresa Sandidge, M.A.; Louisiana: Joan Wightkin; Maine: Martha Henson; Maryland: Diana Cheng, M.D.; Michigan: Yasmina Bouraoui, M.P.H.; Minnesota: Ron Campbell, M.D.;

Mississippi: Linda Pendleton, L.M.S.W.; Montana: JoAnn Dotson; Dr. P.H.; Nebraska: Debbi Barnes-Josiah, Ph.D.; New Jersey: Lakota Kruse, M.D.; New Mexico: Ssu Weng, M.D.; New York State: Anne Radigan-Garcia; New York City: Fabienne Laraque, M.D.; North Carolina: Paul Buescher, Ph.D.; North Dakota: Sandra Anseth, R.N.; Ohio: Adriana Pust; Oklahoma: Dick Lorenz, M.S.; Oregon: Ken Rosenberg, M.D.; Rhode Island: Sam Viner-Brown; South Carolina: Mary Kate Powell; Texas: Ramdas Menon, Ph.D.; Utah: Lois Bloebaum; Vermont: Peggy Brozicevic; Washington: Linda Lohdefinck; West Virginia: Melissa Baker, M.A.; CDC PRAMS Team, Applied Sciences Branch, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion.

References

1. Locksmith GJ, Duff P. Preventing neural tube defects: the importance of periconceptional folic acid supplements. *Obstet Gynecol* 1998;91:1027–34.
2. Scott CL, Chavez GF, Atrash HK, Taylor DJ, Shah RS, Rowley D. Hospitalizations for severe complications of pregnancy, 1987–1992. *Obstet Gynecol* 1997;90:225–9.
3. Jackson GL, Kennedy KA, Sendelbach DM, et al. Problem identification in apparently well neonates: implications for early discharge. *Clin Pediatr* 2000;39:581–90.
4. Guptar P, Bisht HJ. Early discharge of normal term neonates: continued dilemma. *Indian Pediatr* 2001;38:1374–81.
5. Mandl KD, Homer CJ, Harary O, Finkelstein JA. Effect of a reduced postpartum length of stay program on primary care services use by mothers and infants. *Pediatrics* 2000;106:937–41.
6. Beck LF, Morrow B, Lipscomb LE, et al. Prevalence of selected maternal behaviors and experiences, Pregnancy Risk Assessment Monitoring System (PRAMS), 1999. In: *CDC Surveillance Summaries*, April 26, 2002. *MMWR* 2000;51(No. SS-2);1–27.
7. CDC. PRAMS 1999 Surveillance Report. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 2003.
8. CDC. PRAMS 1998 Surveillance Report. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 2000.
9. CDC. PRAMS 1997 Surveillance Report. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 1999.
10. CDC. PRAMS 1996 Surveillance Report. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 1999.
11. CDC. PRAMS 1995 Surveillance Report. Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 1998.
12. US Department of Health and Human Services. *Healthy People 2010*. 2nd. ed. With understanding and improving health and objectives for improving health (2 vols.). Washington DC: US Department of Health and Human Services, 2000.

MMWR now publishes important health information, like reports related to terrorism and other health emergencies, as often as required to protect the public health. MMWR Dispatch provides the latest and most accurate information regarding public health investigations, surveillance, prevention and treatment guidelines, and other clinical information. Visit cdc.gov/mmwr, and sign up to receive MMWR Dispatch by e-mail. In addition to MMWR Dispatch, you'll also receive MMWR Weekly, MMWR Recommendations and Reports, and MMWR Surveillance Summaries. As always, MMWR is also available in print. Anytime MMWR Dispatch is published online, it also appears in the next printed MMWR issue. MMWR Dispatch. Another way MMWR helps you stay current on important public health, clinical, and scientific topics.

know what matters.



13. Colley Gilbert B, Shulman HB, Fischer LA, Rogers MM. The Pregnancy Risk Assessment Monitoring System (PRAMS): methods and 1996 response rates from 11 states. *Matern Child Health J* 1999;3:199–209.
14. Shah BV, Barnwell BG, Bieler GS. SUDAAN user's manual: software for the statistical analysis of correlated data. Release 7.5. Research Triangle Park, NC: Research Triangle Institute, 1997.
15. Scholl TO, Hediger ML, Schall JI, Khoo CS, Fischer RL. Dietary and serum folate: their influence on the outcome of pregnancy. *Am J Clin Nutr* 1996;63:520–5.
16. Botto LD, Khoury MJ, Mulinare J, Erickson JD. Periconceptual multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. *Pediatrics* 1996;98:911–7.
17. Anderson RN. Deaths: leading causes for 2000. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics, 2002. (National vital statistics reports; vol. 50 no. 16).
18. CDC. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR* 1992;41(No. RR-14):1–7.
19. March of Dimes. National perinatal statistics. March of Dimes Birth Defects Foundation. Available at http://www.marchofdimes.com/professionals/680_1239.asp.
20. Bennett TA, Kotelchuck M, Cox CE, Tucker MJ, Nadeau DA. Pregnancy-associated hospitalizations in the United States in 1991 and 1992: a comprehensive view of maternal morbidity. *Am J Obstet Gynecol* 1998;178:346–54.
21. Berg CJ, Bruce FC, Callaghan WM. From mortality to morbidity: the challenge of the twenty-first century. *J Am Med Womens Assoc* 2002;57:173–4.
22. Eaton AP. Early postpartum discharge: recommendations from a preliminary report to congress. *Pediatrics* 2001;107:400–4.
23. American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for perinatal care. Fifth edition. Elk Grove Village, IL: American Academy of Pediatrics, 2002.
24. American Academy of Pediatrics, Committee on Fetus and Newborn. Hospital stay for healthy term newborns. *Pediatrics* 1995;96:788–90. Available at <http://www.aap.org/policy/01033.html>.
25. Brown S, Small R, Faber B, Krastev A, Davis P. Early postnatal discharge from hospital for healthy mothers and term infants (Cochrane Review). In: *The Cochrane Library, Issue 2, 2003*. Oxford: Update Software. CD002958.
26. Zhu B-P, Haines KM, Le T, McGrath-Miller K, Boulton ML. Effect of the interval between pregnancies on perinatal outcomes among white and black women. *Am J Obstet Gynecol* 2001;185:1403–10.
27. Shults RA, Volker A, Olsham AF, Martin CF, Royce RA. Effects of short interpregnancy intervals on small-for-gestational age and preterm births. *Epidemiology* 1999;10:250–4.
28. Fuentes-Afflick E, Hessol NA. Interpregnancy interval and the risk of premature infants. *Obstet Gynecol* 2000;95:383–90.
29. Adams MM, Delaney KM, Stupp PW, McCarthy BJ, Rawlings JS. The relationship of interpregnancy interval to infant birthweight and length of gestation among low-risk women, Georgia. *Paediatr Perinat Epidemiol* 1997;11(suppl 1):48–62.
30. Kallan JE. Reexamination of interpregnancy intervals and subsequent birth outcomes: evidence from US linked birth/infant death records. *Social Biology* 1997; 44(3–4):205–12.
31. Hatcher RA, Trussell J, Stewart F, et al. *Contraceptive technology*. 17th ed. New York: Ardent Media, Inc., 1998.
32. Massai MR, Diaz S, Quinteros E, et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. *Contraception* 2001;64:369–76.
33. Stevens-Simon C, Kelly L, Singer D. Preventing repeat adolescent pregnancies with early adoption of the contraceptive implant. *Fam Plan Perspect* 1999;31(2):88–93.
34. Berenson AB, Wiemann CM. Contraceptive use among adolescent mothers at 6 months postpartum. *Obstet Gynecol* 1997;89:999–1005.
35. Diaz S, Zepeda A, Maturana X, et al. Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices. *Contraception* 1997;56:223–32.
36. D'Angelo D, Colley Gilbert B. From data to action: using surveillance to promote public health. Examples from the Pregnancy Risk Assessment Monitoring System (PRAMS). Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 2002.

Appendix

TABLE. Stratification variables, sample size, and weighted response rates for states participating in the Pregnancy Risk Assessment Monitoring System (PRAMS), 2000

State	Stratification variables	Annual sample size*	Weighted response rate (%) [†]
Alabama	Birthweight (<2,500 g, ≥2,500 g); Medicaid status (yes, no)	2,245	72
Alaska	Birthweight (<2,500g, ≥2,500 g); race (Alaska Native, non-Alaska Native)	1,858	82
Arkansas	Birthweight (<2,500 g, ≥2,500 g); population density (low, medium, high)	2,238	75
Colorado	Birthweight (<2,500 g, ≥2,500 g); region of state (Denver, other metropolitan, rural)	2,974	75
Florida	Birthweight (<2,500g, ≥2,500 g); age (<20 yrs, ≥20 yrs); race (black, nonblack)	2,727	79
Hawaii	Race (Hawaiian Native, non-Hawaiian Native); geographic area (Honolulu resident, other Oahu resident, other resident)	3,183	80
Illinois	Birthweight (<2,500 g, ≥2,500 g)	2,455	83
Louisiana	Birthweight (<1,500 g, ≥1,500 g); region of state (urban, rural)	3,298	72
Maine	Birthweight (<2,500 g, ≥2,500 g)	1,508	78
Nebraska	Race (white, black, Native American, Asian, Hispanic)	2,687	86
New Mexico	Birthweight (<2,500 g, ≥2,500 g)	2,210	73
New York [§]	Birthweight (<2,500 g, ≥2,500 g)	1,721	75
North Carolina	Birthweight (<1,500 g, 1,500–2,499 g, >2,500 g)	2,480	74
Ohio	Birthweight (<2,500 g, ≥2,500 g); race (black, nonblack)	2,438	75
Oklahoma	Birthweight (<1,500 g, 1,500–2,499 g, 2,500–3999 g, ≥4,000 g)	2,535	81
South Carolina	Birthweight (<1,500 g, 1,500–2,499 g, ≥2,500 g)	2,195	78
Utah	Birthweight (<2,500 g, ≥2,500 g); race (black, Asian/Pacific Islander/Native American, white/other)	2,302	80
Washington	Race (Hispanic, black, Asian/Pacific Islander, Native American, white/other); Geographic area (King County, Snohomish County, other county)	2,147	81
West Virginia	Birthweight (<2,500 g, ≥2,500 g); Age (<20 yrs, ≥20 yrs)	1,800	75

* Number of women sampled in a state in 2000.


[†] Response rate adjusted for sample design.

[§] Data do not include New York City.

o·rig·i·nal: *adj*

(ə-'rij-ən-'l) 1 : being the first instance or source from which a copy, reproduction, or translation can be made;

see also *MMWR*.



know what matters.



The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.